Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772284 | 0.90 | RAB9A (0.55) | CYP4F2CYP4A11LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6771544 | 0.79 | ITGB1 (0.51) | LMNAALDH1A1KDM4EL3MBTL1ITGB1 | |
| SCHEMBL7700065 | 0.77 | AKR1C3 (0.66) | AKR1C3AKR1C1LMNAALDH1A1HTT | |
| SCHEMBL6774349 | 0.73 | ITGB3 (0.51) | LMNAALDH1A1SMN1; SMN2KDM4EL3MBTL1 | |
| SCHEMBL6778668 | 0.73 | ITGB3 (0.47) | ITGB1ITGA5 | |
| SCHEMBL610121 | 0.72 | MAPT (0.77) | AKR1C3AKR1C1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL21669903 | 0.72 | MAPT (0.77) | AKR1C3AKR1C1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4701073 | 0.72 | MAPT (0.77) | AKR1C3AKR1C1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL23498075 | 0.71 | AKR1C3 (0.72) | AKR1C3AKR1C1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL24754517 | 0.71 | AKR1C3 (0.72) | AKR1C3AKR1C1LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833366-B1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2004-12-21 | — | — | US | claimed |
| US-6720315-B2 | FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | claimed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | claimed |
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2002-07-25 | — | — | US | claimed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | claimed |
| US-6720315-B2 | FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | disclosed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | ITGA5, ITGB5, ITGB1 | AKR1C3 792/4885CYP4F2 2609/4885CYP4A11 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.